Delve into dermatology diseases with new approaches from conventional to complementary care.
Explore a broad spectrum of dermatological conditions and topics to enhance your practice.
Expert led instruction for every level of patient care.
Log in to see enrolled program content.
Gain practical insights and meet new colleagues.
Hover over a conference to view recordings.
The largest integrative dermatology community.
Bifidobacteriaceae is the primary colonizer of the infant gut and grows better than any other bacteria in infant gut. It has the unique ability to digest and consume human milk oligosaccharide structure. Most important in metabolizing mother's milk!
Strains: B.infantis 35624[3-6] (Align, Proctor and Gamble, Cincinnati, OH), Unknown strain of B. infantis included in VSL#3® probiotic blend[6,7] (Sigma-Tau Pharmaceuticals, Inc., Towson, MD), Strain EVC001[8] (Evivo, Evolve BioSystems), B. infantis CCRC 14633 & B. infantis CCRC 14661[9], B. infantis CGMCC313-2[10] (Kexing Biotech Company Limited, Shenzhen, China)
Listed below are possible uses for different strains of B. infantis with some applications backed by human trials and commercialized for human use. Other uses are theoretical in humans and only investigated in animal models. For more information, see “Evidence for Use” sections that follow.
Symptom reduction in:
Preventative for:
Additional potential uses for:
“Food” stuffs
Supplements:
Multi-ingredient
Farid et al 2011 showed that administration of 7 strains of probiotic bacteria – 1 x 109 CFU twice daily over 8 weeks - and fructooligosaccharide in 40 infants showed improvement of atopic dermatitis[14,15].
Groeger et al. 2013 showed that 1 x 1010 CFU of B. infantis 35624 for 8 weeks for oral administration in adults 18-60 year olds significantly lowered proinflammatory CRP and increased anti-inflammatory cytokine IL-10[5].
Bacterium | Route and Dose (Topical/Oral) | Skin Condition | Outcome |
---|---|---|---|
L. casei, L. rhamnosus, S. thermophilus, B. breve, L. acidophilus, B. infantis, L. bulgaricus |
Oral - 1 x 109 CFU of a mixture of 7 strains including B. infantis, twice daily over 8 weeks |
Atopic Dermatitis in infants |
Significant reduction in “Severity Scoring of Atopic Dermatitis (SCORAD) index”[14] |
B. infantis 35624 |
Oral – 1 x 1010 CFU of B. infantis 35624 over 8 weeks |
Psoriasis in adults 18-60 y/o |
CRP (inflammatory marker) significantly lowered. IL-10 (anti-inflammatory cytokine) increased[5] |
Significant reductions in IBS symptoms in adults of abdominal bloating, cramping, and bowel movement difficulty compared to placebo and other lactobacillus species. [4,6]
VSL#3 probiotic blend which contains B. infantis has been studied for use in ulcerative colitis and prevention of pouchitis in UC patients that have surgical ileal anal pouch. VSL #3 claims that its probiotics work by increasing the amount of “good” commensal bacteria thereby preventing microbial dysbiosis characteristic of UC, and combating intestinal permeability and pathogenic colonization of gut barrier, and decreasing inflammation. Because VSL #3 blend is a combination of bacterial strains it is unclear what absolute effect B. infantis specifically has on UC disease progression. In one study in rat models with TNBS-induced colitis, oral feeding of B. infantis indicated significant reduction in inflammation, mucosal damage, and preservation of goblet cells as compared to control animals.[16]
Other benefits to the immature gut are numerous. In one study, B infantis administration increased growth in very low birth weight infants exposed to antibiotics.[17] In addition, B infantis has been shown to be anti-inflammatory in many in vitro and animal studies reviewed by Underwood et al. 2015. In summary, B. infantis was modeled to decrease the risk of necrotizing entercolitis (NEC) in premature infants through several mechanisms; by suppressing pro-inflammatory cytokines that are involved in pathophysiology of NEC pathology, suppressing NEC-causing bacteria like Cronobacter sakazakii in mouse models, and decreasing intestinal permeability to microbes.[13]
The strain CGMCC313-2 was shown in one study to have a protective effect on mouse models of asthma and food allergy, attenuating allergic inflammation and inhibiting secretion of allergen-induced IgE, IL-4, and IL-13. Mouse models were created through allergen sensitization to produce ovalbumin-induced airway asthma and beta-lactoglobin-induced food allergy states.
Studies of Desbonnet et al. 2008 and 2010 showed that B. infantis treatment may have the potential to shift moods. The 2008 study in rats resulted in attenuation of inflammatory immune responses, and elevation of serotonergic precursor, tryptophan.[18] The latter study showed that B. infantis treatment used on rat maternal separation model of depression in setting of acute stressor of forced swim test resulted in normalization of immune response, reversal of behavior deficits, and restoration of noradrenaline in brainstem.[19]
Chronic Fatigue syndrome, which is an inflammatory disease, was found to modifiable by B. infantis 35624. The strain reduced plasma levels of inflammatory markers C-reactive protein levels, IL-6, and TNF-alpha.[5]